Sun Pharma Q4 Results: Pharmaceutical Company’s profit dropped 19%, improvement in margin; Dividend’s announcement – Sun Pharma Q4 Results 2025 Profit Down Ebitda Up Dividend Announs

Sun pharma Q4 results: Sun Pharmaceutical Industries Ltd, the country’s largest pharmaceutical company, has declared the results of the March 2025 quarter (Q4FY25). Sun Pharma’s performance was largely mixed.

The company’s consolidated revenue rose by 8.1% to ₹ 12,958.8 crore in the March 2025 quarter, which was ₹ 11,982.9 crore in the same quarter last year. However, the figure lagged slightly behind the market estimate. According to the CNBC-TV18 pole, the revenue was expected to reach ₹ 13,039.2 crore.

Large fall in profit

The net profit of Sun Pharma fell 19% to ₹ 2,153.9 crore on an annual basis, compared to ₹ 2,658.7 crore in the same period last year. Analysts hoped that the figure would reach ₹ 2,934 crore. The company is clearly disappointed on this front.

Ebitda and Margin Better

Sun Pharma’s Ebitda rose 22.4% to ₹ 3,715.9 crore, which was ₹ 3,035.15 crore last year. The performance was better than the market estimate (₹ 3,618 crore). The Ebitda margin was 28.7%, which is quite above 25.3% of the previous year. The CNBC-TV18 pole estimated it to be 27.7%, that is, the company also performed better than expected on the margin’s front.

Dividend’s announcement

The Board of Directors of Sun Pharma have recommended a final dividend of ₹ 5.50 per share for FY2024–25. The proposal will be applicable after the approval of shareholders in the company’s upcoming annual general meeting (AGM).

The condition of Sun Pharma shares

The Sun Pharma shares closed at ₹ 1,722.65 with a decline of 0.52% on BSE before the quarter results announced. In the last one year, this pharmaceutical company has given a profit of 11.84%. However, this year i.e. in 2025, the company’s shares have fallen by 8.84% so far.

Also read: Market Outlook: Market closed in red mark, know how it can be on May 23

Disclaimer: Here information provided is being given only for information. It is necessary to mention here that the investment market in the market is subject to risks. Always consult experts before investing money as an investor. There is never advice to anyone to invest money on behalf of Moneycontrol.